09:34 AM EST - BriaCell Therapeutics Corp. : Announced the completion of the Phase I part of the clinical trial of its lead candidate, Bria-IMT, in combination with Incyte’s PD-1 inhibitor, retifanlimab, in advanced breast cancer. BriaCell Therapeutics Corp.
shares T.BCT are trading up $0.68 at $8.60.
